Premium
MiR‐152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17
Author(s) -
Wu Yang,
Huang Aixue,
Li Tao,
Su Xueting,
Ding Hongmei,
Li Hui,
Qin Xingliang,
Hou Lubin,
Zhao Qiang,
Ge Xingfeng,
Fang Tao,
Wang Rong,
Gao Changqing,
Li Jie,
Shao Ningsheng
Publication year - 2014
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2014.04.037
Subject(s) - umbilical vein , human umbilical vein endothelial cell , cleavage (geology) , cell , endothelial stem cell , microbiology and biotechnology , cancer research , cell growth , chemistry , immunology , medicine , biology , biochemistry , in vitro , paleontology , fracture (geology)
As a cleavage enzyme of precursor TNF‐α, the high expression level of ADAM17 in endothelial cells is an important factor in atherosclerosis. In this study, we demonstrate that ADAM17 is the target of miR‐152. We found that miR‐152 could reduce TNF precursor cleavage and inhibit cell proliferation and migration by targeting ADAM17 in human umbilical vein endothelial cells (HUVECs). Furthermore, the expression pattern of miR‐152 and corresponding target ADAM17 was opposite in HUVECs under hypoxic conditions. The levels of circulating miR‐152 in AS patient sera were lower than those detected in the sera of normal individuals. Our results indicate that miR‐152 may be involved in the development of human atherosclerosis and could be used as diagnostic biomarker or therapeutic target in atherosclerosis.